Treating TIR3A thyroid nodules with radiofrequency ablation
Radiofrequency Ablation for Treating Thyroid Nodules Classified as TIR3A, With a Negative Genetic Evaluation for Thyroid Carcinoma
NA · Istituto Auxologico Italiano · NCT05765695
This study is testing whether a procedure called radiofrequency ablation can safely shrink thyroid nodules that are not likely to be cancerous and help patients feel better.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Sex | All |
| Sponsor | Istituto Auxologico Italiano (other) |
| Locations | 1 site (Milan) |
| Trial ID | NCT05765695 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the safety and effectiveness of radiofrequency ablation for treating TIR3A thyroid nodules that have tested negative for genetic mutations associated with thyroid cancer. The study will involve patients with indeterminate thyroid nodules who are at low risk for malignancy, as determined by fine needle aspiration cytology. Participants will undergo a thorough pre-ablation assessment, including blood tests, to ensure they meet eligibility criteria. The primary outcome will be the reduction in nodule size and improvement in clinical symptoms following the procedure.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with TIR3A thyroid nodules that have negative genetic evaluations and are eligible for radiofrequency ablation.
Not a fit: Patients with thyroid nodules that are not classified as TIR3A or those with positive genetic tests for thyroid carcinoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a minimally invasive treatment option for patients with benign thyroid nodules, reducing the need for surgery.
How similar studies have performed: Other studies have shown promising results with radiofrequency ablation for thyroid nodules, suggesting this approach may be effective for similar cases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with thyroid nodule eligible for radiofrequency ablation, with low-risk indeterminate lesion cytology (TIR3A) and negative genetic test for mutations associated with thyroid carcinoma Exclusion Criteria: * Patients who are not able to sign the informed consent * Patients with contraindications to radiofrequency ablation * Patients with cytology different from TIR3A * Patients with positive genetic test for mutations associated with thyroid carcinoma
Where this trial is running
Milan
- Istituto Auxologico Italiano IRCCS — Milan, Italy (RECRUITING)
Study contacts
- Study coordinator: Laura Fugazzola
- Email: l.fugazzola@auxologico.it
- Phone: +390261911
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thyroid Nodule, thyroid nodule, indeterminate, genetic, radiofrequency ablation, follow-up